Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2007

Charles River Inks deal with Shanghai BioExplorer to Form Preclinical Services Company

  • Charles River Laboratories  began expansion into Asia with the signing of a joint venture agreement with Shanghai BioExplorer, a provider of preclinical services, to form Charles River Laboratories Preclinical Services—China.

    As part of this agreement, Charles River will construct a 50,000-square-foot preclinical services facility in Shanghai. The facility, which is expected to open in mid-2008, will provide a range of discovery and development services, including GLP and non-GLP toxicology studies. These services will be designed to meet the FDA’s standards for quality. Charles River intends to use its own research models in the new Shanghai facility.

    The joint venture will be majority owned and controlled by Charles River. The transaction is subject to customary closing conditions, including Chinese regulatory approval, and is expected to close by the end of the second quarter of 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »